"FDA Greenlights Versatile New Antibiotic for Triple Applications"
Originally Published 1 year ago — by FDA.gov
The FDA has approved Zevtera (ceftobiprole medocaril sodium for injection) for the treatment of Staphylococcus aureus bloodstream infections, acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia in adults and pediatric patients. The antibiotic was found to be effective in clinical trials, with common side effects including nausea, diarrhea, and headache. However, patients with a history of severe hypersensitivity to ceftobiprole or cephalosporin antibacterial class should not use Zevtera. The approval was granted with Priority Review, Fast Track, and Qualified Infectious Disease Product designations for the specified indications.